SCHEMBL508700

SCHEMBL508700

CC(C)(C)[Si](C)(C)OCc1ccc(Br)nc1

nearest known ligand 0.42

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.36
GRM2 Q14416 1/20 0.32
PARP1 P09874 1/20 0.31
ALOX5AP P20292 1/20 0.31
FEN1 P39748 1/20 0.31
PREP P48147 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3458584 0.84 CYP11B1 (0.35) CYP11B1GRM2PARP1
SCHEMBL23540665 0.81 DUT (0.37) CYP11B1
SCHEMBL1535653 0.81 TSHR (0.36)
SCHEMBL643187 0.80 GABRP (0.41) ALOX5APFEN1
SCHEMBL34466654 0.80 ALDH1A1 (0.44)
SCHEMBL30423197 0.80 GABRP (0.41) ALOX5APFEN1
SCHEMBL4050106 0.80 APP (0.35)
SCHEMBL2462510 0.80 CYP11B1 (0.36) CYP11B1ALOX5APFEN1
SCHEMBL5311879 0.80 ALDH1A1 (0.44)
SCHEMBL481257 0.79 IDO1 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688772-A1 BIARYL DERIVATIVES AND RELATED USES Moma Therapeutics, Inc. (US) 2026-02-11 EP disclosed
US-20260015360-A1 BIARYL DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2026-01-15 US disclosed
CN-119451961-A Carboxamide derivative with RSK inhibition effect, pharmaceutical composition containing carboxamide derivative and application of carboxamide derivative 广州科恩泰生物医药科技有限公司 2025-02-14 CN disclosed
US-20250026758-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS INC (US) 2025-01-23 US disclosed
CN-119112895-A Muscarinic acetylcholine M1 receptor antagonists 康蒂内乌姆医疗公司 2024-12-13 CN disclosed
US-20240389588-A1 COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2024-11-28 US disclosed
WO-2024211834-A1 BIARYL DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2024-10-10 WO disclosed
US-12054487-B2 Muscarinic acetylcholine M1 receptor antagonists CONTINEUM THERAPEUTICS, INC. (US) 2024-08-06 US disclosed
US-12022832-B2 Compounds and methods for treating nematode infections THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2024-07-02 US disclosed
US-12022832-B2 Compounds and methods for treating nematode infections THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2024-07-02 US disclosed
US-20020022633-A1 Inhibitors of prenyl-protein transferase WILLIAMS THERESA M (US) 2002-02-21 US disclosed
WO-2002002108-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2002-01-10 WO disclosed
EP-0539086-B1 Condensed pyrimidine derivatives and their use as angiotensine II antagonists AMERICAN HOME PROD (US) 1997-12-29 EP disclosed
US-5498776-A Substituted pyrrolopyrimidines and pyridopyrimidines useful as angiotensin II antagonists AMERICAN HOME PRODUCTS CORPORATION (US) 1996-03-12 US disclosed
US-5451583-A Angiotensin inhibitors AMERICAN HOME PRODUCTS CORPORATION (US) 1995-09-19 US disclosed
WO-1994011365-A1 SUBSTITUTED BENZIMIDAZOLES AND QUINAZOLINES AS ANTIHYPERTENSIVES AMERICAN HOME PRODUCTS CORPORATION (US) 1994-05-26 WO disclosed
US-5283242-A Hypotensive agents, cardiotonic agents AMERICAN HOME PRODUCTS CORPORATION (US) 1994-02-01 US disclosed
US-5256654-A Substituted pyrrolopyrimidines, azepinopyrimidines and pyridopyrimidines useful as angiotensin II antagonists AMERICAN HOME PRODUCTS CORPORATION (US) 1993-10-26 US disclosed
EP-0539086-A2 Condensed pyrimidine derivatives and their use as angiotensine II antagonists AMERICAN HOME PRODUCTS CORPORATION (US) 1993-04-28 EP disclosed
US-5149699-A Substituted pyridopyrimidines useful as antgiotensin II antagonists AMERICAN HOME PRODUCTS CORPORATION (US) 1992-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12022832-B2 Compounds and methods for treating nematode infections HNMT, NISCH, HRH2 CYP11B1 469/4885GRM2 2569/4885PARP1 4826/4885
US-20260015360-A1 BIARYL DERIVATIVES AND RELATED USES POLB, POLA1, POLN CYP11B1 77/4885GRM2 3655/4885PARP1 277/4885
US-12054487-B2 Muscarinic acetylcholine M1 receptor antagonists CHRM1, CHRM2, CHRM3 CYP11B1 957/4885GRM2 28/4885PARP1 4092/4885
US-20250026758-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM2, CHRM5 CYP11B1 970/4885GRM2 28/4885PARP1 3976/4885
US-20020022633-A1 Inhibitors of prenyl-protein transferase FNTA, KRAS, FNTB CYP11B1 1882/4885GRM2 4650/4885PARP1 2497/4885
US-20240389588-A1 COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS HNMT, NISCH, HRH2 CYP11B1 469/4885GRM2 2569/4885PARP1 4826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.